share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外國發行人報告（業績相關）
美股SEC公告 ·  08/15 10:52
Moomoo AI 已提取核心訊息
TC BioPharm (Holdings) PLC, a clinical-stage biopharmaceutical company, has successfully closed a public offering on August 15, 2024, raising $2.0 million in gross proceeds. The offering involved the sale of 23,950 American Depositary Shares (ADSs), Pre-Funded Warrants to purchase up to 1,976,050 ADSs, and Series G Purchase Warrants to purchase up to 2,000,000 ADSs. The Warrants, exercisable immediately and expiring one year from issuance, and the Pre-Funded Warrants, exercisable at any time, were offered at a price of $1.00 per ADS and $0.999 per Pre-Funded Warrant, respectively. This offering was made pursuant to a registration statement on Form F-1, declared effective by the SEC on August 12, 2024. The proceeds are intended to support an upcoming clinical trial for Acute Myeloid Leukemia and for general corporate purposes. Additionally, TC BioPharm has regained compliance with the Nasdaq's minimum stockholders' equity requirement, which was previously below the required threshold as of March 31, 2024. The company had been granted an exception by a Nasdaq Hearings Panel and, following the offering, believes it now meets the equity requirement.
TC BioPharm (Holdings) PLC, a clinical-stage biopharmaceutical company, has successfully closed a public offering on August 15, 2024, raising $2.0 million in gross proceeds. The offering involved the sale of 23,950 American Depositary Shares (ADSs), Pre-Funded Warrants to purchase up to 1,976,050 ADSs, and Series G Purchase Warrants to purchase up to 2,000,000 ADSs. The Warrants, exercisable immediately and expiring one year from issuance, and the Pre-Funded Warrants, exercisable at any time, were offered at a price of $1.00 per ADS and $0.999 per Pre-Funded Warrant, respectively. This offering was made pursuant to a registration statement on Form F-1, declared effective by the SEC on August 12, 2024. The proceeds are intended to support an upcoming clinical trial for Acute Myeloid Leukemia and for general corporate purposes. Additionally, TC BioPharm has regained compliance with the Nasdaq's minimum stockholders' equity requirement, which was previously below the required threshold as of March 31, 2024. The company had been granted an exception by a Nasdaq Hearings Panel and, following the offering, believes it now meets the equity requirement.
臨床階段生物製藥公司TC BioPharm (Holdings) PLC已成功於2024年8月15日完成公開募股，籌集200萬美元的總收益。該募集涉及出售23,950股美國存托股票（ADS）、可立即行使、有效期爲發行後一年的G系列認股權證，可購買最多200萬股ADS、可隨時行使、售價爲1.00美元/ADS的預付款認股權證，售價分別爲1.00美元/ADS和0.999美元/預付款認股權證。該募集基於一份在2024年8月12日被美國證券交易委員會（SEC）宣佈生效的F-1表格註冊聲明進行。所籌集的資金旨在支持急性髓性白血病的即將展開的臨床試驗以及用於普通企業用途。此外，TC BioPharm已重新符合納斯達克最低股東權益要求，該要求在2024年3月31日前曾低於要求門檻。該公司獲得了納斯達克聽證會的豁免，並經過募股後認爲現在符合股東權益要求。
臨床階段生物製藥公司TC BioPharm (Holdings) PLC已成功於2024年8月15日完成公開募股，籌集200萬美元的總收益。該募集涉及出售23,950股美國存托股票（ADS）、可立即行使、有效期爲發行後一年的G系列認股權證，可購買最多200萬股ADS、可隨時行使、售價爲1.00美元/ADS的預付款認股權證，售價分別爲1.00美元/ADS和0.999美元/預付款認股權證。該募集基於一份在2024年8月12日被美國證券交易委員會（SEC）宣佈生效的F-1表格註冊聲明進行。所籌集的資金旨在支持急性髓性白血病的即將展開的臨床試驗以及用於普通企業用途。此外，TC BioPharm已重新符合納斯達克最低股東權益要求，該要求在2024年3月31日前曾低於要求門檻。該公司獲得了納斯達克聽證會的豁免，並經過募股後認爲現在符合股東權益要求。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息